Immune safety of a novel oncolytic mutant M1 after administration In Vivo

Abstract

The aim of this study was to evaluate the safety and efficiency of a novel, oncolytic adenovirus mutant M1 administered in conjunction with immunosuppressive agents. Animal models were established by administering purified M1 either intravenously or retroperitoneally. At different time points, blood samples were taken from the mice for testing of liver and renal function. Microscopic examination of the liver was performed to observe pathological changes. Immunohistochemical analyses were used to evaluate the expression of the adenovirus in the liver. Lymphocyte recruitment to the liver and the activation of adenovirus specific T cells were also analyzed. No signs of general toxicity were observed, but transient increases in ALT and Scr were observed following the administration of M1. Microscopic examination revealed a mild inflammatory response in the liver. Compared to intravenous injection, higher expression levels of adenoviral proteins were observed after retroperitoneal injection. Combined treatment with cyclosporine A resolved the liver and kidney dysfunction and increased the concentration of the adenovirus in the liver. The use of the novel oncolytic adenovirus mutant M1 in vivo is safe, and the combined administration of M1 with immunosuppressive agents was able to enhance the effectiveness and safety profile of M1.

Keywords

adenovirus M1 / immunity / safety

References

[1] MizuguchiH., HayakawaT.. Targeted adenovirus vectors. HumGene Ther, 2004, 15(11): 1034-1044

[2] WeiQ., LiuZ., FeiY., et al.. Adeno-associated viral vector mediated and cardiac-specific delivery of CD151 gene in ischemic rat hearts. J Huazhong Univ Sci Technol Med Sci, 2011, 31(1): 46-51

[3] ZhouJ., GaoQ., ChenG., et al.. Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability. Clin Cancer Res, 2005, 11(23): 8431-8440

[4] MorralN., O’NealW.K., RiceK., et al.. Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther, 2002, 13(1): 143-154

[5] SullivanD.E., DashS., DuH., et al.. Liver-directed gene transfer in non-human primates. Hum Gene Ther, 1997, 8(10): 1195-1206

[6] ZamirG., GelmanA.E., OlthoffK.M., et al.. Patterns of transgene expression and viral clearance from the transplanted liver following ex vivo adenovirus-mediated gene transfer. J Hepatol, 2004, 41(5): 714-720

[7] BessisN., GarciacozarF.J., BoisserM.C.. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther, 2004, 11(1): 10-17

[8] BouvetM., FangB., EkmekciogluS., et al.. Suppression of immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther, 1985, 5(2): 189-195

[9] KawaharaT., MurakamiS., NoiriY., et al.. Effects of cyclosporine-A-induced immunosuppression on periapical lesions in rats. J Dent Res, 2004, 83(9): 683-687